SCHEMBL5575155

SCHEMBL5575155

O=C(COc1cccc(C(F)(F)F)c1)CP(=O)(O)O

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.63
MAOB P27338 2/20 0.51
AOC3 Q16853 1/20 0.51
MRGPRX4 Q96LA9 1/20 0.49
ACP3 P15309 1/20 0.49
KMT2A Q03164 2/20 0.47
MEN1 O00255 1/20 0.47
POLB P06746 1/20 0.47
ALDH1A1 P00352 3/20 0.47
GAA P10253 3/20 0.47
LMNA P02545 2/20 0.47
MAPT P10636 2/20 0.47
HTT P42858 1/20 0.47
NR4A2 P43354 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 1/20 0.45
ENPP2 Q13822 1/20 0.45
RXFP1 Q9HBX9 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13641800 0.89 KDM4E (0.63) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL187207 0.85 KDM4E (0.59) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL187208 0.85 KDM4E (0.55) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL12722064 0.84 KDM4E (0.57) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL11633334 0.83 KDM4E (0.56) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL5571188 0.81 KDM4E (0.63) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL8510279 0.81 KDM4E (0.63) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL2550199 0.81 KDM4E (0.63) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL5575636 0.81 KDM4E (0.57) KDM4EMAOBAOC3MRGPRX4KMT2A
SCHEMBL5575640 0.81 KDM4E (0.57) KDM4EMAOBAOC3MRGPRX4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7166730-B2 Process for the preparation of prostaglandin derivatives FINE TECH LABORATORIES, LTD (IL) 2007-01-23 US disclosed
US-20050209337-A1 Process for the preparation of prostaglandin derivatives FINETECH LABORATORIES LTD 2005-09-22 US disclosed
US-6353000-B1 INTRAOCULAR HYPERTENSION TREATMENT ALCON LABORATORIES, INC. 2002-03-05 US disclosed
US-5770759-A 13,14-DIHYDRO-15-KETO-PGF'S; VASOPRESSORS R-TECH UENO, LTD. (JP) 1998-06-23 US disclosed
WO-1998020880-A2 11-HALO PROSTAGLANDINS FOR THE TREATMENT OF GLAUCOMA OR OCULAR HYPERTENSION ALCON LABORATORIES, INC. (US) 1998-05-22 WO disclosed
US-5591887-A 13,14-DIHYDRO-15-KETO-PGFS R-TECH UENO, LTD. (JP) 1997-01-07 US disclosed
US-5221763-A 13,14-dihydro-15-keto-PGFs and salts R-TECH UENO, LTD. (JP) 1993-06-22 US disclosed
US-5106869-A Vasopressor activity without ephemeral vasorelaxation; no effect on trachea, intestine K.K. UENO SEIYAKU OYO KENKYUJO (JP) 1992-04-21 US disclosed
EP-0289349-B1 PROSTAGLANDINS OF THE F SERIES Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo (JP) 1992-01-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050209337-A1 Process for the preparation of prostaglandin derivatives PTGIS, PTGES, PTGIR KDM4E 4475/4885MAOB 1250/4885AOC3 2821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.